Epidemiology and economic burden of "serious" adverse drug reactions: Real-world evidence research based on pharmacovigilance data.

Date publication

décembre 2021

Journal

Therapie

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NERICH Virginie

Tous les auteurs :
Tissot M, Valnet-Rabier MB, Stalder T, Limat S, Davani S, Nerich V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35012757

Résumé

Serious adverse drug reactions account for 3.6% of French hospital admissions. Of these, 48.5% are, at least potentially, preventable. The first aim of post-marketing pharmacovigilance is to detect adverse drug reactions as a safety signal to improve patients' safety. Thus, this study describes the epidemiology of "serious" adverse drug reactions reported between 2015 and 2018 to a regional pharmacovigilance centre and assesses their economic burden.

Mots clés

Adverse drug reaction, Drugs, Economic burden of disease, Epidemiology, Pharmacovigilance

Référence

Therapie. 2021 Dec 15;: